Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) EV/FCF
As of 5 November 2026, Roivant Sciences Ltd. (ROIV) trades at a EV/FCF of −28.1×. Over the past ten years it has ranged from −32.4× (September 2026) to 0.0× (March 2021); the current reading is higher than 1% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2026 | −20.4× | — |
| FY2025 | −3.3× | — |
| FY2024 | −2.8× | — |
| FY2023 | −4.7× | — |
| FY2022 | −2.1× | — |
| FY2021 | −7.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −26.8× | — |
| Mar 2026 | −20.4× | — |
| Dec 2025 | −14.2× | — |
| Sep 2025 | −8.0× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. | −28.1× |
| RVMD Revolution Medicines, Inc. compare | −25.0× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 27.1× |
| RPRX Royalty Pharma PLC compare | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement